A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis
| Condition | Ulcerative Colitis, Ulcerative Colitis Chronic |
|---|---|
| Phase | Phase 3 |
| Sponsor | Eli Lilly and Company |
| Status | Completed |
| Enrollment | 172 participants |
| Interventions | Mirikizumab, Mirikizumab |
| Start date | May 17, 2023 |
| Completion date | Aug 9, 2024 |
| Results posted | Sep 30, 2025 |
Summary
A study to investigate bowel urgency in adults with moderately to severely active ulcerative colitis (UC) treated with mirikizumab. The study will have 4 periods and will last for 36 weeks.
Change From Baseline in Bowel Urgency Severity Urgency Numeric Rating Scale (UNRS)
| 300 mg Mirikizumab | -3.25 score on a scale |
|---|
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Coliti — Janssen Research & Development, LLC
- GI Permeability Change in Response to Aquamin® — James Varani
- A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Seve — Hoffmann-La Roche
- A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerativ — Janssen Research & Development, LLC
- A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Mode — Janssen Research & Development, LLC
- Efficacy and Mechanism of Fecal Microbiota Transplantation of the Bai Ethnicity in the Tre — First Affiliated Hospital of Kunming Medical University